Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% After Better-Than-Expected Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s stock price traded up 5.8% during trading on Friday following a better than expected earnings announcement. The company traded as high as $1.74 and last traded at $1.7350. 1,928,143 shares were traded during trading, a decline of 35% from the average session volume of 2,946,142 shares. The stock had previously closed at $1.64.

The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The business had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $3.14 million.

Key Headlines Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations: GAAP EPS of -$0.04 vs. consensus -$0.07 and revenue of $5.49M vs. $3.14M — the upside to both EPS and revenue supports near-term optimism. Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M
• Positive Sentiment: Clinical and corporate progress: management said pivotal sotagliflozin milestones remain on schedule (NDA resubmission in T1D, SONATA enrollment for HCM) and pilavapadin received a positive End-of-Phase 2 FDA meeting supporting Phase 3 readiness — these de-risk upcoming catalysts. The company also reported >$100M of additional cash from a capital raise and a Novo Nordisk milestone, strengthening the balance sheet. Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
• Positive Sentiment: Analyst upgrade / price-target lift: HC Wainwright reiterated a Buy and raised its PT from $4 to $6, implying substantial upside from current levels — analyst support can attract buying interest. Benzinga coverage of HC Wainwright PT raise
• Neutral Sentiment: Conference materials and call transcripts available: the company filed a press release, slide deck and held a conference call (transcripts available) — useful for digging into guidance, cash runway and trial timelines but not a direct price driver by itself. View Press Release / Slide Deck
• Neutral Sentiment: Multiple outlets published earnings call transcripts and snapshots (Seeking Alpha, InsiderMonkey, Yahoo, WTOP) — increases transparency and coverage but mainly reiterates the same beats and updates. InsiderMonkey earnings call transcript
• Negative Sentiment: Company remains unprofitable with negative ROE and net margin; consensus still expects a full-year EPS loss (current consensus ~ -$0.66). Continued clinical and regulatory risk plus negative earnings projections mean upside depends on successful trial and regulatory outcomes. MarketBeat company profile and consensus estimates

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LXRX shares. Wall Street Zen cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. HC Wainwright raised their target price on shares of Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.63.

Insider Buying and Selling

In other news, Director Invus Global Management, Llc acquired 1,538,462 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the purchase, the director directly owned 1,538,462 shares of the company’s stock, valued at $2,000,000.60. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Debbane acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the purchase, the director directly owned 1,904,186 shares in the company, valued at $2,799,153.42. This trade represents a 5.54% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 1,790,462 shares of company stock worth $2,369,981 over the last quarter. 13.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in shares of Lexicon Pharmaceuticals by 27.4% in the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 29,319 shares in the last quarter. Invesco Ltd. increased its position in shares of Lexicon Pharmaceuticals by 173.5% during the 1st quarter. Invesco Ltd. now owns 285,759 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 181,265 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $541,000. Acadian Asset Management LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth about $263,000. Finally, Savant Capital LLC increased its position in Lexicon Pharmaceuticals by 33.2% during the second quarter. Savant Capital LLC now owns 69,578 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 17,348 shares during the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Stock Up 4.6%

The stock has a market cap of $623.35 million, a P/E ratio of -9.03 and a beta of 0.94. The firm has a 50 day simple moving average of $1.35 and a 200-day simple moving average of $1.33. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.